# Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

> **NCT00286455** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 329 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin
- **DRUG:** Alogliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00286455
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00286455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00286455, "Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00286455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*